Cholinergic Drugs for Alzheimer’s Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer’s Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery.
The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer’s Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention.
1. Chapter 1. Introduction - p. 3 2. Chapter 2. Current hypothesis for AD progression - p. 7 3. Chapter 3. Neurotransmitter systems and peripheral nerve system - p. 45 4. Chapter 4. ACh receptors in ACh transmission - p. 55 5. Chapter 5. Choline esterase - p. 61 6. Chapter 6. Cholinergic ACh, AChE, and its inhibitors - p. 79 7. Chapter 7. Classification of ChE inhibitors by binding mode - p. 93 8. Chapter 8. Classification of ChE inhibitors by action mechanism - p. 99 9. Chapter 9. Clinical status of ChE inhibitors - p. 109 10. Chapter 10. AChE inhibitors - p. 113 11. Chapter 11. Forthcoming generation of AChE inhibitors - p. 135 12. Chapter 12. Hybrid inhibitors - p. 143 13. Chapter 13. AChR-targeted drugs for AD treatment - p. 153 14. Chapter 14. Cholinergic neuromuscular junction and its blocking agents (blockers) - p. 161 15. Chapter 15. Nonadrenergic and noncholinergic neurotransmitters - p. 165 16. Chapter 16. Protein kinase inhibitors for treatment of Alzheimer’s disease - p. 169 17. Chapter 17. Inhibition of cholinergic inflammation via acetylcholinesterase inhibitor interaction with α4β2 nAChR and α7nAChR, not AChE enzyme inhibition - p. 175 18. Chapter 18. NMDA and non-NMDA receptor antagonism for Alzheimer’s disease treatment - p. 181 19. Chapter 19. Challenges in recent Alzheimer's disease therapeutic approaches - p. 189 20. Chapter 20. Identification and application of biomarkers for Alzheimer's disease - p. 229 21. Chapter 21. Artificial intelligence (AI)-assisted AD target and drug discovery - p. 233 22. Chapter 22. Conclusion and perspectives - p. 241 23. Section II. Natural alkaloidal and non-alkaloidal anti-AChE and anti-Alzheimer’s disease compounds in the symptomatic intimation of Alzheimer’s disease - p. S2 24. Chapter 23. Introduction - p. 249 25. Chapter 24. Current bioactive molecules in Alzheimer's disease therapy - p. 253 26. Chapter 25. Emerging lead compounds from naturally occurring molecules for Alzheimer's disease therapy - p. 257 27. Chapter 26. Natural anti-AChE compounds for Alzheimer's disease therapy - p. 259 28. 26.1 Alkaloid compounds as anti-AChE inhibitors for AD therapy - p. 260 29. 26.2 Nonalkaloid compounds as AChE inhibitors for AD therapy - p. 272 30. 26.3 NonChE inhibitory but Aβ and NFT inhibitory natural products by β/γ-secretase inhibition and α-secretase enhancement in AD - p. 293 31. 26.4 Miscellaneous AD preventive and therapeutic drugs - p. 303 32. Chapter 27. Molecular docking simulation for consistency between SAR results and in vitro AChE inhibitory activities - p. 327 33. Chapter 28. Conceptual search for MTDs of plant natural compounds for multifactorial Alzheimer's disease therapy - p. 335 34. Chapter 29. AChE inhibitors in daily consumable cereals and food resources - p. 359 35. Chapter 30. Conclusion and perspective - p. 365 36. Section III. Marine AChE inhibitors for the symptomatic treatment of Alzheimer’s disease - p. S3 37. Chapter 31. Introduction - p. 369 38. Chapter 32. Localization, structure and cellular function of AChE - p. 375 39. Chapter 33. AChE inhibitors from marine resources - p. 379 40. Chapter 34. Non-ChE inhibitory anti-Alzheimer's disease compounds - p. 419 41. Chapter 35. Emerging concept of dual-target drug and multi-target drug in AD pathology and promising AD drugs - p. 429 42. Chapter 36. Conclusion and prospectives - p. 441 43. Index - p. 455
Cholinergic Drugs for Alzheimer’s Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer’s Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery.
The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer’s Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention.
1. Chapter 1. Introduction - p. 3 2. Chapter 2. Current hypothesis for AD progression - p. 7 3. Chapter 3. Neurotransmitter systems and peripheral nerve system - p. 45 4. Chapter 4. ACh receptors in ACh transmission - p. 55 5. Chapter 5. Choline esterase - p. 61 6. Chapter 6. Cholinergic ACh, AChE, and its inhibitors - p. 79 7. Chapter 7. Classification of ChE inhibitors by binding mode - p. 93 8. Chapter 8. Classification of ChE inhibitors by action mechanism - p. 99 9. Chapter 9. Clinical status of ChE inhibitors - p. 109 10. Chapter 10. AChE inhibitors - p. 113 11. Chapter 11. Forthcoming generation of AChE inhibitors - p. 135 12. Chapter 12. Hybrid inhibitors - p. 143 13. Chapter 13. AChR-targeted drugs for AD treatment - p. 153 14. Chapter 14. Cholinergic neuromuscular junction and its blocking agents (blockers) - p. 161 15. Chapter 15. Nonadrenergic and noncholinergic neurotransmitters - p. 165 16. Chapter 16. Protein kinase inhibitors for treatment of Alzheimer’s disease - p. 169 17. Chapter 17. Inhibition of cholinergic inflammation via acetylcholinesterase inhibitor interaction with α4β2 nAChR and α7nAChR, not AChE enzyme inhibition - p. 175 18. Chapter 18. NMDA and non-NMDA receptor antagonism for Alzheimer’s disease treatment - p. 181 19. Chapter 19. Challenges in recent Alzheimer's disease therapeutic approaches - p. 189 20. Chapter 20. Identification and application of biomarkers for Alzheimer's disease - p. 229 21. Chapter 21. Artificial intelligence (AI)-assisted AD target and drug discovery - p. 233 22. Chapter 22. Conclusion and perspectives - p. 241 23. Section II. Natural alkaloidal and non-alkaloidal anti-AChE and anti-Alzheimer’s disease compounds in the symptomatic intimation of Alzheimer’s disease - p. S2 24. Chapter 23. Introduction - p. 249 25. Chapter 24. Current bioactive molecules in Alzheimer's disease therapy - p. 253 26. Chapter 25. Emerging lead compounds from naturally occurring molecules for Alzheimer's disease therapy - p. 257 27. Chapter 26. Natural anti-AChE compounds for Alzheimer's disease therapy - p. 259 28. 26.1 Alkaloid compounds as anti-AChE inhibitors for AD therapy - p. 260 29. 26.2 Nonalkaloid compounds as AChE inhibitors for AD therapy - p. 272 30. 26.3 NonChE inhibitory but Aβ and NFT inhibitory natural products by β/γ-secretase inhibition and α-secretase enhancement in AD - p. 293 31. 26.4 Miscellaneous AD preventive and therapeutic drugs - p. 303 32. Chapter 27. Molecular docking simulation for consistency between SAR results and in vitro AChE inhibitory activities - p. 327 33. Chapter 28. Conceptual search for MTDs of plant natural compounds for multifactorial Alzheimer's disease therapy - p. 335 34. Chapter 29. AChE inhibitors in daily consumable cereals and food resources - p. 359 35. Chapter 30. Conclusion and perspective - p. 365 36. Section III. Marine AChE inhibitors for the symptomatic treatment of Alzheimer’s disease - p. S3 37. Chapter 31. Introduction - p. 369 38. Chapter 32. Localization, structure and cellular function of AChE - p. 375 39. Chapter 33. AChE inhibitors from marine resources - p. 379 40. Chapter 34. Non-ChE inhibitory anti-Alzheimer's disease compounds - p. 419 41. Chapter 35. Emerging concept of dual-target drug and multi-target drug in AD pathology and promising AD drugs - p. 429 42. Chapter 36. Conclusion and prospectives - p. 441 43. Index - p. 455
